UNILAT is applied across domains where additional symptomatic support is needed, relevant in contexts involving acute or fluctuating symptom patterns. Addressing symptomatic discomfort is a core part of managing both acute and long-term health concerns. UNILAT is considered relevant within clinical settings that involve management of symptoms associated with acute or episodic changes, helping to address symptom clusters that may appear suddenly or fluctuate. It is commonly used for managing symptoms related to systemic imbalance, heightened physiological activity, and functional stress. This application is particularly relevant across conditions characterized by periods of heightened symptoms and contexts marked by increased discomfort or tension.

The medicine supports the management of symptoms that interfere with daily functioning or create noticeable physiological strain. It is helpful when short-term symptomatic assistance is needed, offering supportive relief that helps patients cope more steadily when symptoms are more noticeable. The medicine may assist with easing distress during symptomatic phases.

Quick Fact: Used for managing Episodic Symptoms

Regulatory References

1. MedlinePlus overview on Pain

Eligibility Map: Who can and cannot use UNILAT

The official eligibility profile for UNILAT (Latanoprost) is defined by regulatory bodies through specific contraindications and required cautions for certain populations.

Populations for whom use is contraindicated: Use is strictly prohibited for patients with a known hypersensitivity to the active substance, Latanoprost, or to any of the product's inactive ingredients, including benzalkonium chloride.

Age-related eligibility rules: The medicine is approved for use in adults, and no geriatric-specific limitations have been identified. While approved in some regions for children from 4 years of age, US regulatory status often notes that safety and effectiveness in pediatric patients have not been established.

Pregnancy and lactation eligibility status: The medicine should not be used during pregnancy due to unestablished safety and the potential for hazardous pharmacological effects. Similarly, it should not be used by breastfeeding women, as Latanoprost and its metabolites may pass into breast milk.

Condition-specific restrictions: Caution is officially advised for patients with a history of iritis/uveitis or active herpes simplex keratitis (where avoidance is recommended). Furthermore, caution is required for patients with risk factors for cystoid macular edema, such as those who are aphakic or pseudophakic with certain lens complications. Use requires special consideration in patients with known severe hepatic or renal impairment due to limited safety data in these populations.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns and restrictions for the active ingredient, Latanoprost, based strictly on government regulatory sources.

Drug-Drug Interactions (Pharmacodynamic & Timing-Based)

Prostaglandin Analogues (Not Recommended)

Co-administration of two or more prostaglandins or prostaglandin analogues, such as UNILAT and medicines like bimatoprost or travoprost, is formally not recommended. This constraint is due to a documented pharmacodynamic conflict which may lead to the counter-intuitive and potentially detrimental increase of internal eye pressure (IOP), reversing the intended therapeutic effect.

Ophthalmic Products Requiring Separation

An administration-timing interaction exists with all other topical ophthalmic products. To ensure proper absorption and efficacy, these agents must be administered at least five (5) minutes apart from UNILAT. This timing rule is specifically mandated for ophthalmic solutions containing thimerosal to prevent a documented in vitro physical incompatibility and precipitation reaction.

Metabolic, Transporter, and Substance Interactions

Official regulatory labeling does not document restrictions or mandatory adjustments related to drug-drug interactions mediated by cytochrome P450 (CYP) enzymes or drug transporters. Furthermore, specific interaction patterns with food, alcohol, supplements, or herbal products are not explicitly detailed in major government prescribing information for latanoprost ophthalmic solution.

Targeted Activation of the Prostaglandin F Receptor

The mechanism of Latanoprost involves highly localized, targeted actions that modulate the structure of ocular outflow tissues. The drug's active form, Latanoprost Acid, functions as a selective agonist at the Prostaglandin F Receptors (FP Receptors) found on the ciliary muscle. This targeted receptor activation engages a signaling cascade necessary to remodel the tissue architecture, leading to reduced intraocular pressure.

Remodeling the Extracellular Matrix and Enhancing Fluid Drainage

Activating the FP Receptor triggers a cascade that increases the enzymatic activity of Matrix Metalloproteinases (MMPs). These enzymes remodel the structural components of the tissue, increasing the spaces between the ciliary muscle fibers and lowering resistance to fluid flow. This structural change results in the physiological consequence of enhancing the flow of aqueous humor through the uveoscleral outflow pathway, thereby maintaining a lower intraocular pressure. This maximal effect is delayed, as it depends on the time required for structural tissue remodeling to occur, and the mechanism is constrained by potential receptor desensitization resulting from high frequency of activation.

The usage of UNILAT (Latanoprost ophthalmic solution) involves its administration as a Topical Ophthalmic Solution at a concentration of 0.005%. The regimen involves the application of one drop into the affected eye(s) once daily, with administration recommended in the evening. This frequency is critical, as the dosage must not exceed once daily, which is associated with a decrease in the intended pressure-lowering effect.

Procedural Rules and Timing

When co-administering UNILAT with other topical ophthalmic drugs, they must be administered at least five minutes apart. If a dose is missed, the standard procedure is to skip the forgotten dose and continue treatment with the next dose as scheduled; a double dose is not permitted. Patients who wear soft contact lenses must remove them before the application of the drops, and reinsertion should be delayed until 15 minutes after administration has been completed.

Population and Co-use Constraints

The standard, once-daily posology applies to older adults as well as the general adult population. Regarding the pediatric population, dosing applications vary, and safety and efficacy have not been established in the youngest age groups. A key constraint on co-use is the restriction against combining UNILAT with other prostaglandin ophthalmic drugs, as this combination may lead to a paradoxical reduction in the drug's effect.

Research Evidence for UNILAT: A Clinical Overview

The clinical evaluation of UNILAT, which contains the active ingredient latanoprost, is based primarily on Randomized Controlled Trials (RCTs). These are formal research studies that were designed to research examined UNILAT under controlled conditions. The evidence base also includes large-scale analyses of real-world use and studies that followed patient patterns over longer periods. This overview summarizes what types of research have been conducted, the outcomes they monitored, and what aspects of the medicine's profile are still being studied.

---

Evidence for Use in Open-Angle Glaucoma and Ocular Hypertension (Adults)

The bulk of the clinical evidence for UNILAT was studied for its evaluation in the context of elevated pressure inside the eyes of adults with Open-Angle Glaucoma or Ocular Hypertension. These conditions are frequently associated with acute or disruptive episodes of heightened pressure.

Researchers primarily used RCTs. These studies focused on measuring the change in Intraocular Pressure (IOP) from baseline, as well as monitoring the status of the optic nerve and the health of the visual field. The findings indicate that the research highlights measurements taken during the study period. Studies report patterns related to the IOP, with the maximum observed change in pressure typically recorded between eight and twelve hours in the studied populations. Long-term observational research describes IOP measurements taken over defined time intervals, with some studies monitoring responses for up to five years. The findings describe patterns observed in the studies related to how patients reported their experience and IOP measurements over time.

A key research limitation is that while studies consistently monitored IOP change, there is limited information for long-term outcomes specifically regarding the relationship with the long-term course of progressive visual field loss over many decades.

---

Evidence in Paediatric Populations

Research also examined UNILAT in paediatric patients, which includes children aged four years and older, as well as adolescents, who have elevated IOP or paediatric glaucoma. Studies monitored these populations to assess Intraocular Pressure (IOP) values and to gather information on the medicine's handling by the body.

The available research includes dedicated, but limited, clinical trials and studies examining the systemic exposure of the active metabolite in younger children. Data for certain groups remain insufficient, especially for very young children (infants under three years of age) with complex conditions like Primary Congenital Glaucoma (PCG). Pharmacokinetic research describes patterns related to what appears to be a higher systemic exposure to the active metabolite in younger children compared to adults. Follow-up durations were limited for this population, and the evidence quality varies across studies, with a degree of regulatory reliance on the established adult profile.

Common questions about UNILAT (FAQ)

Q: Can UNILAT be taken long-term?

Official product information indicates that studies have examined latanoprost over extended periods, up to five years. The research demonstrated a stable effect on lowering eye pressure during this prolonged treatment. No signs of tolerance or diminishing effectiveness were observed in these long-term studies.

Q: Does UNILAT have to be taken at the exact same time every day?

The official prescribed regimen for UNILAT specifies application once daily in the evening. Regulatory guidelines state that this frequency should not be exceeded, as taking the medication more often can potentially decrease the intended pressure-lowering effect. Consistency in the evening timing is considered important for achieving optimal therapeutic results.

Q: Can people with kidney problems use UNILAT?

Official documents indicate that caution is advised when latanoprost is used in patients with severe hepatic (liver) or renal (kidney) impairment. This is based on limited available safety data collected for these patient populations.

Q: What is the risk of allergic reaction to UNILAT?

According to official regulatory labeling, UNILAT is contraindicated for anyone with a known hypersensitivity or allergy to the active ingredient, latanoprost, or any of its components. Serious allergic reactions, known as anaphylaxis, have been reported rarely during postmarketing experience.

Q: Is UNILAT more of a preventive or an acute treatment?

UNILAT is indicated for treating chronic conditions like Open-Angle Glaucoma and Ocular Hypertension. Its mechanism of action involves a gradual remodeling of eye tissue to enhance fluid drainage, which takes time to achieve the full pressure-lowering effect. Therefore, it is used for sustained management rather than for immediate, acute relief.

Q: What is the mechanism of action of UNILAT, in simple terms?

The way UNILAT works is by increasing the rate at which fluid inside the eye, called aqueous humor, can drain out. It achieves this by activating specific receptors that enhance a natural drainage route, known as the uveoscleral outflow pathway. This leads to a sustained lowering of the pressure inside the eye.

Q: What does it mean if UNILAT has a 'Black Box Warning'?

The official US Food and Drug Administration (FDA) labeling for latanoprost does not include a Boxed Warning. A Boxed Warning, sometimes referred to as a Black Box Warning, is the strictest warning the FDA requires for prescription drugs to alert healthcare providers and patients about serious risks.

Q: Is it okay to drive while using UNILAT?

Official labeling indicates that if transient blurred vision occurs immediately after applying the eye drops, caution is necessary. It is recommended to wait until your vision clears completely before driving or operating any machinery.

Q: Is UNILAT known to cause sleepiness or fatigue?

While specific data on frequency is not certain and often comes from postmarketing surveillance, some patients have reported experiencing dizziness and headache. Additionally, 'unusual tiredness or weakness' (fatigue) has also been reported in association with the drug's use.

Q: Will UNILAT affect my blood pressure?

Regulatory safety information reports that certain systemic cardiovascular events have been associated with latanoprost use, although they are rare. These events include aggravation of angina (a type of chest pain) in patients with pre-existing conditions and palpitations (a fast, fluttering heartbeat).

Q: How long does UNILAT typically stay in your system after the last dose?

Studies show that the active substance, latanoprost acid, is metabolized rapidly by the liver. It has a very short elimination half-life from the bloodstream of approximately 17 minutes. However, the pressure-lowering effect in the eye is designed to last for at least 24 hours.

Q: What are the most common side effects that led to people stopping UNILAT in studies?

The most common side effects observed in clinical trials, with an incidence of 5–15%, include blurred vision, burning/stinging, conjunctival hyperemia, foreign body sensation, and increased iris pigmentation. Increased iris pigmentation, which can be permanent, is also a known concern that leads some patients to discontinue the medicine.

Q: How often do people using UNILAT report a stomach upset?

While 'stomach upset' is not a specific adverse reaction listed in official documents, the gastrointestinal event of diarrhea has been reported in postmarketing surveillance. The frequency of this side effect is currently not certain.

Q: Can UNILAT be taken with pain relievers like ibuprofen?

Official information suggests that oral non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are generally not expected to interfere with the pressure-lowering effect of UNILAT in the eye. It remains important to ensure your prescribing physician is aware of all concomitant medications.

Q: How does the effectiveness of UNILAT change over time?

Research indicates that UNILAT maintains a stable intraocular pressure-lowering effect over time. Studies have found no evidence of tolerance development or diminishing effectiveness during periods of prolonged treatment.

Q: Can UNILAT be used by someone with a heart condition?

Regulatory safety information includes rare reports of cardiovascular events associated with latanoprost use. These events include palpitations and the aggravation of angina (chest pain) in patients with pre-existing heart disease.

Q: What happens if I stop taking UNILAT suddenly?

When latanoprost therapy is discontinued, the pressure-lowering effect on the eye does not cease immediately. Studies have shown that the effect on intraocular pressure may persist for at least 14 days following the last dose.

Storage and Disposal Conditions

Storage Phase	Temperature and Protection Requirements
Unopened Bottle	Must be stored in a refrigerator (2 C to 8 C or 36 F to 46 F) [Source 1.5, 1.7]. Do not freeze.
Opened Bottle	May be stored at room temperature up to 25 C (77 F) [Source 1.5]. Must be used within 28 days (four weeks) [Source 1.5, 3.6].

Both opened and unopened bottles must be kept in the original outer carton to protect from light [Source 1.5, 1.7]. The container must be kept tightly closed when not in use [Source 1.2].

Child-Safety and Integrity: This medicine must be kept out of the sight and reach of children [Source 1.2]. Do not use the solution after the expiry date on the label [Source 1.5].

Disposal: The product must not be disposed of via household waste or wastewater [Source 1.5]. Any unused medicine or waste material must be disposed of according to local pharmaceutical waste requirements [Source 1.5].